The nation of Zimbabwe has declined a substantial American health deal valued at $367m (£272m) over five years due to the United States' insistence on sensitive biological samples.
This move came to light following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesman later clarified that the US was seeking health data for research and profit but refused to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged continued negotiations to find a deal suitable to both sides so the country's vital HIV programme can continue.
Wider Context
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a similar deal with the US following legal challenges were raised about the safety of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump stated its expenditure was "wasteful" and his administration was seeking government-to-government deals to boost openness and accountability.
As per statements, Sixteen African countries have to date agreed to these new health pacts, representing over $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," his statement read.
"Put simply, our nation would supply the raw materials for scientific discovery without any certainty that the end products would be accessible to our people should a future health crisis arise."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending systems already set up through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation provides its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued dialogue with our American counterparts on how future collaboration might be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
Medical experts said it understood the official position, but recommended that talks need to persist given that much of the nation's Aids initiatives were funded by external financing.
"Where technical issues exist, such as those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it added.
The situation highlights the continuing tensions between accepting much-needed foreign assistance and protecting local interests in an increasingly interconnected world.